Acumen reports positive Phase 1 results for ACU193; Q2 net loss $11.6M, cash $172.2M + $122M offering

Acumen Pharmaceuticals, Inc.

2023-Q2 EPS reported -$0.56

Phase 1 INTERCEPT-AD trial met primary/secondary objectives; ACU193 showed 25% amyloid plaque reduction at 60 mg/kg (p=0.01).
ACU193 demonstrated near-maximal target engagement of toxic AβOs; low ARIA-E rate of 10.4%, symptomatic 2.1%; no drug-related SAEs.
Cash, equivalents & securities $172.2M at June 30; July follow-on offering added ~$122M net; runway into H2 2026.
Phase 2 study initiation expected H1 2024; FDA interaction anticipated Q4 2023 to inform development path.
Q2 2023 net loss $11.6M vs $10.2M YoY; R&D expenses $9.1M (up from $7.3M); no revenue.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acumen Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $11.6 million for the three-month period ended June 30, 2023.

Period: the quarter ended June 30, 2023
Net income: Net loss was $11.6 million for the three-month period ended June 30, 2023
Result: reported results

Exact text from the filing

Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.